Alzheimer´s DiseaseVogelNCT02224326
Vagus Somatosensory Evoked Potentials and Near-infrared Spectroscopy in the Early Diagnosis of Dementia
An observational study of Alzheimer´s Disease, run by University of Wuerzburg at 1 site in Germany.
Trial summary
In its long preclinical course, AD shows a spreading pattern of specific pathology in a uniform sequence of predictable steps including brainstem nuclei in early stages. Many of these nuclei which are early involved in AD take equally part in the afferences of the Xth cranial nerve, the Vagus nerve. Read more about this study
- Who is it for?
- Ages 70 to 78 yearsHealthy volunteers can take part
- Conditions the study is for
- Alzheimer´s Disease
- How many people
- 604 participants
- Where
- 1 siteGermany
- Study dates
- Jun 2011to Jan 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 70 to 78 years
- All sexes
- Healthy volunteers accepted
- Older adult
Study population: Inhabitants of Wuerzburg, the 130 000 inhabitants capital of the german district Lower Franconia who are born between 1.4.1936 and 31.3.1941
Who may be able to join
- inhabitant of Wuerzburg
- born between 1.4.1936 and 31.3.1941
- able to give informed consent
Who cannot join
- manifestation of - apart from dementia - other severe psychiatric disease such as Schizophrenia, neurologic disease such as Parkinson´s disease or stroke or intern disease such as cancer within the past 12 months
- severe, uncorrected see or hearing disturbance
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Prospective Study to Evaluate the Predictive Value of Vagus Somatosensory Evoked Potentials (VSEP) and Near-infrared Spectroscopy (NIRS) in the Early Diagnosis of Alzheimer´s Disease
In its long preclinical course, AD shows a spreading pattern of specific pathology in a uniform sequence of predictable steps including brainstem nuclei in early stages. Many of these nuclei which are early involved in AD take equally part in the afferences of the Xth cranial nerve, the Vagus nerve. A method for the functional assessment of Vagus-related nuclei in the lower brainstem is the technique of somatosensory evoked potentials of the Vagus nerve (VSEP). This method targets the accessibility of early functional changes by evoked potentials on one hand and the early affection of specific brainstem nuclei comprising Vagus afferences in the course of AD on the other hand. The method of VSEP takes advantage of the transcutaneous stimulation of the auricular branch of the Vagus nerve (ABVN) which is presumed to be the only sensory part of this nerve innervating parts of the outer meatus acoustics at the tragus. This cutaneous branch was shown to gain access to Vagus afferences via brainstem regions which are affected in the course of AD. VSEP latencies in AD were shown to be significantly longer as compared to healthy controls. Yet, if VSEP really are suited for the early detection of AD is still not known.
Functional near-infrared spectroscopy (fNIRS) measures changes in cerebral oxygenation by means of near-infrared light using wavelengths of 650-850 nm. The principle of fNIRS is based on the principle that regional neuronal activation of the brain leads to an increase in metabolism and oxygenation of brain tissue in that region which is accompanied by an elevated regional cerebral blood flow. In AD, there is a growing body of literature reporting deviant fNIRS activation patterns for a variety of tasks. For example, it was shown that the fNIRS activation pattern in frontal and parietal cortex areas in subjects with AD performing the line orientation paradigm is clearly different from healthy controls. Yet, if fNIRS is suited as a means of early detection of AD is not known.
Therefore we aimed at testing the predictive value of VSEP and fNIRS in the early detection of AD. The hypothesis to be tested within this study states that subjects developing AD or MCI within an observation period of 6 years depict longer VSEP latencies, a different fNIRS oxygenation pattern and a lower performance in neuropsychologic rating below the level of dementia at baseline than those who remain cognitively stable.
Read the detailed description
With the increasing life span of our population, the prevalence of dementia syndromes is increasing. The most frequent cause of dementia is Alzheimer´s disease (AD), and still, it is not curable. Thus, AD is of increasing medical, social and economic importance.
Intensive scientific work within the past 30 years has identified a range of different factors contributing to the pathogenesis of AD. These complex processes result in specific therapeutic options which are currently investigated in clinical trials. Regardless of the considered risk factor or the specific therapeutic intervention, treatment should be started as early in the excessive preclinical process of AD as possible since it can interfere with the formation of amyloid plaques or neurofibrils. Especially neuroprotective interventions are more effective the less neurons are irreversibly damaged.Therefore, an early diagnosis of developing or incipient AD should be of utmost importance. Likewise, in the light of therapeutic options specific for AD, its differential diagnosis from other forms of dementia seems important.
Therefore, an ideal examination method should not only be easy to conduct, cost effective, repeatable, non-invasive and without discomfort for patients, but it should in particular detect early stages of disease and it should, if possible, consider the development of AD-specific changes. Obviously, today´s routine examination methods in the diagnosis of AD or MCI such as magnetic resonance imaging, cerebrospinal fluid analysis or positron emission tomography do not fulfil all of these requirements. Thus, in the absence of a single diagnostic test and realizing the necessity to combine biomarkers to increase the diagnostic accuracy there is still need for methods that circumvent all those disadvantages.
Since early cellular changes of the disease are expected to impact brain function long before severe morphological alterations occur, these changes should primarily be investigated using functional examination which can be conducted with neurocognitive methods such as intensive neuropsychological rating or with electrophysiological or functional brain imaging methods.
Neuropsychological rating Prior studies investigated the predictive validity of different cognitive measures for the development of AD such as associative learning, verbal fluency and constructive praxis. As such, verbal and non-verbal memory, visual-spatial and executive functions and verbal fluency with executive component seem to be suited for following the deterioration of cognition. In subjects who later develop AD or MCI as compared to a healthy controls, worse performance in episodic memory according (Delayed Verbal and Visual Memory und Associative Learning) and in semantic verbal fluency are known to be characteristic. An extended neuropsychologic testing to measure these cognitive processes thus seems reasonable in particular to evaluate the additional benefit of other diagnostic methods.
Vagus somatosensory evoked potentials (VSEP) As we know today, AD has a long preclinical course with a spreading pattern of specific AD pathology such as neurofibrillary tangles in a uniform sequence of predictable steps. Many of these nuclei which are early involved in AD like the Locus caeruleus, parabrachial nucleus or Raphe nuclei take equally part in the afferences of the Xth cranial nerve, the Vagus nerve. Our laboratory used a hypothesis-driven approach to develop a method for the functional assessment of Vagus-related nuclei in the lower brainstem which resulted in the technique of somatosensory evoked potentials of the Vagus nerve (VSEP). This method targets the accessibility of early functional changes by evoked potentials on one hand and the early affection of specific brainstem nuclei comprising Vagus afferences in the course of AD on the other hand.
The method of VSEP takes advantage of the transcutaneous stimulation of the auricular branch of the Vagus nerve (ABVN). It is presumed to be the only sensory part of this nerve innervating parts of the outer meatus acoustics at the tragus. This cutaneous branch was shown to gain access to Vagus afferences via the Solitary tract nucleus which is affected in the course of AD as well.
The technique of VSEP meanwhile is well characterized from a methodological point of view. There are numerous findings suggesting that observed potentials are generated at brainstem level and can be detected as far field potentials at the scalp without any side effects. VSEP are reproducible and amplitudes as well as latencies are in the range of corresponding parameters of acoustic evoked potentials. Detailed examinations with functional magnetic imaging revealed a cortical activation pattern upon ABVN stimulation comparable to the activation pattern as response to the conventional invasive stimulation of the main Vagus branch. In a subsequent work, even involvement of brainstem activation was demonstrated that could be related to ascending Vagus nerve projections.
As such, VSEP were proposed as a possible means for the early detection of AD and mild cognitive impairment (MCI). VSEP latencies in both groups were shown to be significantly longer as compared to healthy controls. No difference in VSEP parameters was found in patients with Vascular dementia and Major depression.
Near-infrared spectroscopy (NIRS) NIRS measures changes in cerebral oxygenation by means of near-infrared light using wavelengths of 650-850 nm. The principle of NIRS is based on the principle of neurovascular coupling stating that regional neuronal activation of the brain leads to an increase in metabolism and oxygenation of brain tissue in that region which is accompanied by an elevated regional cerebral blood flow. This in turn leads to an increased oxygen saturation with elevated concentrations of oxygenated haemoglobin and diminished concentrations of deoxygenated haemoglobin.
In the last years, functional NIRS (fNIRS) was increasingly applied to measure changes in oxygen saturation of cortical areas during a variety of cognitive tasks such as for example verbal fluency test and thus to detect specific cortical activation not only in the visual and the motor system, but also in cortical areas relevant for cognitive tasks such as prefrontal and parietal cortex that remain stable and are replicable. In AD, there is a growing body of literature reporting deviant fNIRS activation patterns for a variety of tasks. For example, young healthy subjects displayed a distinct activation pattern of the prefrontal cortex during a verbal fluency test (VFT) showing a left hemispheric lateralization which decreased with age without a decline in behavioural performance. In contrast, subjects with AD showed a worse behavioural performance and an even more severe decrease of prefrontal activation as well as a reduced left lateralization as compared to an age-adjusted healthy control group. Likewise, it was shown that the fNIRS activation pattern in frontal and parietal cortex areas in subjects with AD performing the line orientation paradigm is clearly different from healthy controls.
Aim of the study To summarize, VSEP, fNIRS and neuropsychological rating are able to differentiate AD from healthy controls. From a theoretical point of view, these methods should even be suited as a means of detection of the disease in early phases as well. If they are really suited as means for that purpose is to be examined in the here presented study. Therefore we aimed at testing the predictive value of these methods in the early detection of AD. In the here presented research project, 600 subjects examined at baseline by means of VSEP, fNIRS and extended neuropsychological, somatic and laboratory examination are to be reexamined 3 and 6 years later. The hypothesis to be tested within this study states that subjects developing AD or MCI within the observation period depict longer VSEP latencies, a different fNIRS oxygenation pattern and a lower performance in neuropsychologic rating below the level of dementia at baseline than those who remain cognitively stable.
- Conditions
- Alzheimer´s Disease
- Keywords
- Alzheimer´s disease, early diagnosis, evoked potentials, near-infrared spectroscopy
- Medical subject headings
- Disease
What is being measured
The primary outcome is the main question the study is designed to answer.
Mini Mental State Examination (MMSE)
Measured: 6 years
Secondary outcomes (1)
Dementia detection test
Measured: 6 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Aug 2014 (estimated)
- Study startJun 2011
- Primary completionJan 2023
- Study completionJan 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Alzheimer´s DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 604 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Wuerzburg
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Thomas Polak, University of Wuerzburg
- Investigators
- Jürgen Deckert, MD, Principal investigator, University Clinic Wuerzburg, Dept. of Psychiatry, Psychosomatics and Psychotherapy, Fuechsleinstrasse 15, D-97080 Wuerzburg, GermanyThomas Polak, MD, Study director, University Clinic Wuerzburg and Hephata Diakonie, Hauptstraße 280, D-63879 Weibersbrunn, GermanyMartin J Herrmann, PhD, Study director, University Clinic Wuerzburg, Dept. of Psychiatry, Psychosomatics and Psychotherapy, Fuechsleinstrasse 15, D-97080 Wuerzburg, GermanyMartin Lauer, MD, Study director, University Clinic Wuerzburg, Dept. of Psychiatry, Psychosomatics and Psychotherapy, Fuechsleinstrasse 15, D-97080 Wuerzburg, Germany
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02224326
- Sponsor's protocol ID
- Vogel-1
- Acronym
- Vogel
- Status last verified
- Oct 2023
- First submitted
- 7 Sep 2013
- Last updated
- 10 Oct 2023
- Results posted
- No
- Data monitoring committee
- No
Publications
Katzorke A, Zeller JBM, Muller LD, Lauer M, Polak T, Deckert J, Herrmann MJ. Decreased hemodynamic response in inferior frontotemporal regions in elderly with mild cognitive impairment. Psychiatry Res Neuroimaging. 2018 Apr 30;274:11-18. doi: 10.1016/j.pscychresns.2018.02.003. Epub 2018 Feb 11.
PubMed 29472145Zeller JBM, Katzorke A, Muller LD, Breunig J, Haeussinger FB, Deckert J, Warrings B, Lauer M, Polak T, Herrmann MJ. Reduced spontaneous low frequency oscillations as measured with functional near-infrared spectroscopy in mild cognitive impairment. Brain Imaging Behav. 2019 Feb;13(1):283-292. doi: 10.1007/s11682-018-9827-y.
PubMed 29362991Polak T, Herrmann MJ, Muller LD, Zeller JBM, Katzorke A, Fischer M, Spielmann F, Weinmann E, Hommers L, Lauer M, Fallgatter AJ, Deckert J. Near-infrared spectroscopy (NIRS) and vagus somatosensory evoked potentials (VSEP) in the early diagnosis of Alzheimer's disease: rationale, design, methods, and first baseline data of the Vogel study. J Neural Transm (Vienna). 2017 Nov;124(11):1473-1488. doi: 10.1007/s00702-017-1781-0. Epub 2017 Sep 1.
PubMed 28864837Herrmann MJ, Wuttke A, Breuninger L, Eff J, Ettlinger S, Fischer M, Gotzelmann A, Gram A, Pomper LD, Schneider E, Schwitalla L, Siminski N, Spielmann F, Weinmann E, Weyel V, Zeller JBM, Lauer M, Deckert J, Polak T. Functional near-infrared spectroscopy and vagus somatosensory evoked potentials add to the power of established parameters such as poor cognitive performance, dsyosmia and APOe genotype to predict cognitive decline over 8 years in the elderly. J Neural Transm (Vienna). 2025 Mar;132(3):455-468. doi: 10.1007/s00702-024-02859-y. Epub 2024 Nov 13.
PubMed 39535568
Study at a glance
From the registry record, last updated by the sponsor on 10 Oct 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Study to Evaluate the Predictive Value of Vagus Somatosensory Evoked Potentials (VSEP) and Near-infrared Spectroscopy (NIRS) in the Early Diagnosis of Alzheimer´s Disease
- ClinicalTrials.gov ID
- NCT02224326
- Acronym / sponsor ID
- Vogel / Vogel-1
- Conditions
- Alzheimer´s Disease
- Keywords
- Alzheimer´s disease, early diagnosis, evoked potentials, near-infrared spectroscopy
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 604 participants (actual)
- Lead sponsor
- University of WuerzburgUniversity, hospital or other
- Study start
- Jun 2011
- Primary completion
- Jan 2023 (actual)
- Study completion
- Jan 2023 (actual)
- First posted
- 25 Aug 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In its long preclinical course, AD shows a spreading pattern of specific pathology in a uniform sequence of predictable steps including brainstem nuclei in early stages. Many of these nuclei which are early involved in AD take equally part in the afferences of the Xth cranial nerve, the Vagus nerve. A method for the functional assessment of Vagus-related nuclei in the lower brainstem is the technique of somatosensory evoked potentials of the Vagus nerve (VSEP). This method targets the accessibility of early functional changes by evoked potentials on one hand and the early affection of specific brainstem nuclei comprising Vagus afferences in the course of AD on the other hand. The method of VSEP takes advantage of the transcutaneous stimulation of the auricular branch of the Vagus nerve (ABVN) which is presumed to be the only sensory part of this nerve innervating parts of the outer meatus acoustics at the tragus. This cutaneous branch was shown to gain access to Vagus afferences via brainstem regions which are affected in the course of AD. VSEP latencies in AD were shown to be significantly longer as compared to healthy controls. Yet, if VSEP really are suited for the early detection of AD is still not known.
Functional near-infrared spectroscopy (fNIRS) measures changes in cerebral oxygenation by means of near-infrared light using wavelengths of 650-850 nm. The principle of fNIRS is based on the principle that regional neuronal activation of the brain leads to an increase in metabolism and oxygenation of brain tissue in that region which is accompanied by an elevated regional cerebral blood flow. In AD, there is a growing body of literature reporting deviant fNIRS activation patterns for a variety of tasks. For example, it was shown that the fNIRS activation pattern in frontal and parietal cortex areas in subjects with AD performing the line orientation paradigm is clearly different from healthy controls. Yet, if fNIRS is suited as a means of early detection of AD is not known.
Therefore we aimed at testing the predictive value of VSEP and fNIRS in the early detection of AD. The hypothesis to be tested within this study states that subjects developing AD or MCI within an observation period of 6 years depict longer VSEP latencies, a different fNIRS oxygenation pattern and a lower performance in neuropsychologic rating below the level of dementia at baseline than those who remain cognitively stable.
Detailed description
With the increasing life span of our population, the prevalence of dementia syndromes is increasing. The most frequent cause of dementia is Alzheimer´s disease (AD), and still, it is not curable. Thus, AD is of increasing medical, social and economic importance.
Intensive scientific work within the past 30 years has identified a range of different factors contributing to the pathogenesis of AD. These complex processes result in specific therapeutic options which are currently investigated in clinical trials. Regardless of the considered risk factor or the specific therapeutic intervention, treatment should be started as early in the excessive preclinical process of AD as possible since it can interfere with the formation of amyloid plaques or neurofibrils. Especially neuroprotective interventions are more effective the less neurons are irreversibly damaged.Therefore, an early diagnosis of developing or incipient AD should be of utmost importance. Likewise, in the light of therapeutic options specific for AD, its differential diagnosis from other forms of dementia seems important.
Therefore, an ideal examination method should not only be easy to conduct, cost effective, repeatable, non-invasive and without discomfort for patients, but it should in particular detect early stages of disease and it should, if possible, consider the development of AD-specific changes. Obviously, today´s routine examination methods in the diagnosis of AD or MCI such as magnetic resonance imaging, cerebrospinal fluid analysis or positron emission tomography do not fulfil all of these requirements. Thus, in the absence of a single diagnostic test and realizing the necessity to combine biomarkers to increase the diagnostic accuracy there is still need for methods that circumvent all those disadvantages.
Since early cellular changes of the disease are expected to impact brain function long before severe morphological alterations occur, these changes should primarily be investigated using functional examination which can be conducted with neurocognitive methods such as intensive neuropsychological rating or with electrophysiological or functional brain imaging methods.
Neuropsychological rating Prior studies investigated the predictive validity of different cognitive measures for the development of AD such as associative learning, verbal fluency and constructive praxis. As such, verbal and non-verbal memory, visual-spatial and executive functions and verbal fluency with executive component seem to be suited for following the deterioration of cognition. In subjects who later develop AD or MCI as compared to a healthy controls, worse performance in episodic memory according (Delayed Verbal and Visual Memory und Associative Learning) and in semantic verbal fluency are known to be characteristic. An extended neuropsychologic testing to measure these cognitive processes thus seems reasonable in particular to evaluate the additional benefit of other diagnostic methods.
Vagus somatosensory evoked potentials (VSEP) As we know today, AD has a long preclinical course with a spreading pattern of specific AD pathology such as neurofibrillary tangles in a uniform sequence of predictable steps. Many of these nuclei which are early involved in AD like the Locus caeruleus, parabrachial nucleus or Raphe nuclei take equally part in the afferences of the Xth cranial nerve, the Vagus nerve. Our laboratory used a hypothesis-driven approach to develop a method for the functional assessment of Vagus-related nuclei in the lower brainstem which resulted in the technique of somatosensory evoked potentials of the Vagus nerve (VSEP). This method targets the accessibility of early functional changes by evoked potentials on one hand and the early affection of specific brainstem nuclei comprising Vagus afferences in the course of AD on the other hand.
The method of VSEP takes advantage of the transcutaneous stimulation of the auricular branch of the Vagus nerve (ABVN). It is presumed to be the only sensory part of this nerve innervating parts of the outer meatus acoustics at the tragus. This cutaneous branch was shown to gain access to Vagus afferences via the Solitary tract nucleus which is affected in the course of AD as well.
The technique of VSEP meanwhile is well characterized from a methodological point of view. There are numerous findings suggesting that observed potentials are generated at brainstem level and can be detected as far field potentials at the scalp without any side effects. VSEP are reproducible and amplitudes as well as latencies are in the range of corresponding parameters of acoustic evoked potentials. Detailed examinations with functional magnetic imaging revealed a cortical activation pattern upon ABVN stimulation comparable to the activation pattern as response to the conventional invasive stimulation of the main Vagus branch. In a subsequent work, even involvement of brainstem activation was demonstrated that could be related to ascending Vagus nerve projections.
As such, VSEP were proposed as a possible means for the early detection of AD and mild cognitive impairment (MCI). VSEP latencies in both groups were shown to be significantly longer as compared to healthy controls. No difference in VSEP parameters was found in patients with Vascular dementia and Major depression.
Near-infrared spectroscopy (NIRS) NIRS measures changes in cerebral oxygenation by means of near-infrared light using wavelengths of 650-850 nm. The principle of NIRS is based on the principle of neurovascular coupling stating that regional neuronal activation of the brain leads to an increase in metabolism and oxygenation of brain tissue in that region which is accompanied by an elevated regional cerebral blood flow. This in turn leads to an increased oxygen saturation with elevated concentrations of oxygenated haemoglobin and diminished concentrations of deoxygenated haemoglobin.
In the last years, functional NIRS (fNIRS) was increasingly applied to measure changes in oxygen saturation of cortical areas during a variety of cognitive tasks such as for example verbal fluency test and thus to detect specific cortical activation not only in the visual and the motor system, but also in cortical areas relevant for cognitive tasks such as prefrontal and parietal cortex that remain stable and are replicable. In AD, there is a growing body of literature reporting deviant fNIRS activation patterns for a variety of tasks. For example, young healthy subjects displayed a distinct activation pattern of the prefrontal cortex during a verbal fluency test (VFT) showing a left hemispheric lateralization which decreased with age without a decline in behavioural performance. In contrast, subjects with AD showed a worse behavioural performance and an even more severe decrease of prefrontal activation as well as a reduced left lateralization as compared to an age-adjusted healthy control group. Likewise, it was shown that the fNIRS activation pattern in frontal and parietal cortex areas in subjects with AD performing the line orientation paradigm is clearly different from healthy controls.
Aim of the study To summarize, VSEP, fNIRS and neuropsychological rating are able to differentiate AD from healthy controls. From a theoretical point of view, these methods should even be suited as a means of detection of the disease in early phases as well. If they are really suited as means for that purpose is to be examined in the here presented study. Therefore we aimed at testing the predictive value of these methods in the early detection of AD. In the here presented research project, 600 subjects examined at baseline by means of VSEP, fNIRS and extended neuropsychological, somatic and laboratory examination are to be reexamined 3 and 6 years later. The hypothesis to be tested within this study states that subjects developing AD or MCI within the observation period depict longer VSEP latencies, a different fNIRS oxygenation pattern and a lower performance in neuropsychologic rating below the level of dementia at baseline than those who remain cognitively stable.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 70 to 78 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Older adult
- Study population
- Inhabitants of Wuerzburg, the 130 000 inhabitants capital of the german district Lower Franconia who are born between 1.4.1936 and 31.3.1941
Key inclusion criteria (3 listed)
- inhabitant of Wuerzburg
- born between 1.4.1936 and 31.3.1941
- able to give informed consent
Key exclusion criteria (2 listed)
- manifestation of - apart from dementia - other severe psychiatric disease such as Schizophrenia, neurologic disease such as Parkinson´s disease or stroke or intern disease such as cancer within the past 12 months
- severe, uncorrected see or hearing disturbance
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Mini Mental State Examination (MMSE)
Time frame: 6 years
1 secondary outcome
Dementia detection test
Time frame: 6 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Oct 2023.
- Background: PubMed 29472145Katzorke A, Zeller JBM, Muller LD, Lauer M, Polak T, Deckert J, Herrmann MJ. Decreased hemodynamic response in inferior frontotemporal regions in elderly with mild cognitive impairment. Psychiatry Res Neuroimaging. 2018 Apr 30;274:11-18. doi: 10.1016/j.pscychresns.2018.02.003. Epub 2018 Feb 11.
- Background: PubMed 29362991Zeller JBM, Katzorke A, Muller LD, Breunig J, Haeussinger FB, Deckert J, Warrings B, Lauer M, Polak T, Herrmann MJ. Reduced spontaneous low frequency oscillations as measured with functional near-infrared spectroscopy in mild cognitive impairment. Brain Imaging Behav. 2019 Feb;13(1):283-292. doi: 10.1007/s11682-018-9827-y.
- Background: PubMed 28864837Polak T, Herrmann MJ, Muller LD, Zeller JBM, Katzorke A, Fischer M, Spielmann F, Weinmann E, Hommers L, Lauer M, Fallgatter AJ, Deckert J. Near-infrared spectroscopy (NIRS) and vagus somatosensory evoked potentials (VSEP) in the early diagnosis of Alzheimer's disease: rationale, design, methods, and first baseline data of the Vogel study. J Neural Transm (Vienna). 2017 Nov;124(11):1473-1488. doi: 10.1007/s00702-017-1781-0. Epub 2017 Sep 1.
- Derived from this study: PubMed 39535568Herrmann MJ, Wuttke A, Breuninger L, Eff J, Ettlinger S, Fischer M, Gotzelmann A, Gram A, Pomper LD, Schneider E, Schwitalla L, Siminski N, Spielmann F, Weinmann E, Weyel V, Zeller JBM, Lauer M, Deckert J, Polak T. Functional near-infrared spectroscopy and vagus somatosensory evoked potentials add to the power of established parameters such as poor cognitive performance, dsyosmia and APOe genotype to predict cognitive decline over 8 years in the elderly. J Neural Transm (Vienna). 2025 Mar;132(3):455-468. doi: 10.1007/s00702-024-02859-y. Epub 2024 Nov 13.
Related trials for Alzheimer´s Disease
RecruitingPhase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Alzheimer s Disease, Mild Cognitive Impairment
Active, not recruitingPhase 2
Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers
Arterial Stiffness, White Matter Lesions
Not yet recruitingObservational study
Chinese University-Alzheimer's Disease With Vascular and Other Co-pathology: Towards Actionable Neuro-Cognitive-Omic Evaluations (CU-ADVANCE)
Alzheimer s Disease, Mild Cognitive Impairment (MCI)
RecruitingObservational study
Development, Validation and Normative Data of the Italian Battery for the Recognition of Famous Faces (FAME)
Stroke, Alzheimer s Disease
RecruitingPhase 1
An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease
Alzheimer s Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jürgen Deckert, MD principal investigator
University Clinic Wuerzburg, Dept. of Psychiatry, Psychosomatics and Psychotherapy, Fuechsleinstrasse 15, D-97080 Wuerzburg, Germany
Thomas Polak, MD study director
University Clinic Wuerzburg and Hephata Diakonie, Hauptstraße 280, D-63879 Weibersbrunn, Germany
Martin J Herrmann, PhD study director
University Clinic Wuerzburg, Dept. of Psychiatry, Psychosomatics and Psychotherapy, Fuechsleinstrasse 15, D-97080 Wuerzburg, Germany
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Alzheimer´s Disease, run by University of Wuerzburg at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mini Mental State Examination (MMSE) (time frame: 6 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02224326, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Oct 2023.